Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Blood|November 26, 2002
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cellsRamadevi Nimmanapalli, Lianne Fuino, Corinne Stobaugh, et al.The Journal of Investigative Dermatology|November 22, 2005
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic actionChunlei Zhang, Victoria Richon, Xiao Ni, et al.Bioorganic & Medicinal Chemistry Letters|May 18, 2007
Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitorsSandro Belvedere, David J Witter, Jiaming Yan, et al.Journal of Cellular Biochemistry|April 27, 2004
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2Purva Bali, Michael Pranpat, Ramona Swaby, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cellsWarren Fiskus, Michael Pranpat, Maria Balasis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignanciesOwen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.Plos One|September 27, 2017
Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibitionMichael Lampa, Heike Arlt, Timothy He, et al.Journal of Proteome Research|April 16, 2009
Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometryAnita Y H Lee, Cloud P Paweletz, Roy M Pollock, et al.The American Journal of Pathology|May 22, 2010
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasisElisa Benedettini, Lynette M Sholl, Michael Peyton, et al.Pageof 2